Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Krauss, DanielKestin, Larry
Ye, Hong
Brabbins, Donald
Ghilezan, Michel
Gustafson, Gary
Vicini, Frank
Martinez, Alvaro
Affiliation
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI 48073,, USA. dkrauss@beaumont.eduIssue Date
2012-02-01T10:03:07ZMeSH
AgedAndrogen Antagonists/*therapeutic use
Brachytherapy/methods
Combined Modality Therapy/methods
Humans
Male
Prostate-Specific Antigen/blood
Prostatic Neoplasms/blood/*drug therapy/mortality/pathology/*radiotherapy
Radiotherapy Dosage
Regression Analysis
Survival Analysis
Treatment Outcome
Metadata
Show full item recordCitation
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1064-71. Epub 2010 Jun 26.Journal
International journal of radiation oncology, biology, physicsDOI
10.1016/j.ijrobp.2010.04.004PubMed ID
20584576Abstract
PURPOSE: Assessment of androgen deprivation therapy (ADT) benefits for prostate cancer treated with dose-escalated radiotherapy (RT). METHODS AND MATERIALS: From 1991 to 2004, 1,044 patients with intermediate- (n = 782) or high-risk (n = 262) prostate cancer were treated with dose-escalated RT at William Beaumont Hospital. Patients received external-beam RT (EBRT) alone, brachytherapy (high or low dose rate), or high dose rate brachytherapy plus pelvic EBRT. Intermediate-risk patients had Gleason score 7, prostate-specific antigen (PSA) 10.0-19.9 ng/mL, or Stage T2b-T2c. High-risk patients had Gleason score 8-10, PSA >/=20, or Stage T3. Patients were additionally divided specifically by Gleason score, presence of palpable disease, and PSA level to further define subgroups benefitting from ADT. RESULTS: Median follow-up was 5 years; 420 patients received ADT + dose-escalated RT, and 624 received dose-escalated RT alone. For all patients, no advantages in any clinical endpoints at 8 years were associated with ADT administration. No differences in any endpoints were associated with ADT administration based on intermediate- vs. high-risk group or RT modality when analyzed separately. Patients with palpable disease plus Gleason >/=8 demonstrated improved clinical failure rates and a trend toward improved survival with ADT. Intermediate-risk patients treated with brachytherapy alone had improved biochemical control when ADT was given. CONCLUSION: Benefits of ADT in the setting of dose-escalated RT remain poorly defined. This question must continue to be addressed in prospective study.Language
engISSN
1879-355X (Electronic)0360-3016 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2010.04.004
Scopus Count
Collections
Related articles
- Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
- Authors: Demanes DJ, Brandt D, Schour L, Hill DR
- Issue date: 2009 Aug
- Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
- Authors: Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA
- Issue date: 2013 Mar 1
- Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
- Authors: Zapatero A, Valcárcel F, Calvo FA, Algás R, Béjar A, Maldonado J, Villá S
- Issue date: 2005 Sep 20
- Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
- Authors: Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J
- Issue date: 2005 Aug 1
- High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
- Authors: Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J
- Issue date: 2006